🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Latvian Early Atherosclerosis Registry

Recruitingn/aAges 18 Years - 65 YearsAllPauls Stradins Clinical University Hospital
NCT06393894 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Atherosclerosis and its complications are a global problem. There are several widely known and proven risk factors that promotes atherogenesis in the majority of patients. However, significant proportion of apparently healthy and young patients with cardiovascular disease but yet without recognized atherogenesis promoting risk factors can be observed in clinical practice. It highlights the need of new risk markers for early atherosclerosis diagnostics to prevent serious cardiovascular complications in these patients and in population in general. The interest in the negative impact of genetic variance, gene regulation on atherogenesis is growing. Therefore the purpose of this study is to analyze the impact of genetic variance and microRNA expression on early atherosclerosis development in the population of young, apparently healthy patients with coronary atherosclerosis. The primary hypot

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion criteria: * Signed informed consent * Early atherosclerosis defined as coronary atherosclerosis in men aged \<55 years and women \<65 years * Coronary artery atherosclerosis with angiographically proven coronary vessel luminal stenosis ≥ 50% and ischaemia * Coronary artery atherosclerosis with planned revascularization * History of coronary artery revascularization (PTCA or coronary artery bypass surgery) * Coronary vessel suitable for NIRS pullback Exclusion criteria: * Diabetes * Total cholesterol ≥7 mmol/l and/or LDL ≥ 5 mmol/l * family hypercholesterolemia * positive family history of early cardiovascular disease (myocardial infarction, sudden cardiac death or cardiovascular disease of first degree relatives at young age - men \<55 years, women \<65 years) * malignant or resistant hypertension ≥ 10 years * body mass index ≥40 kg/m 2 ) * 20 or more pack years of smoking
💊

What it tests

  • Near infrared spectroscopy
  • Genetic testing for LDLR, APOB, PCSK9 and LDLRAP1 mutations and niR-126, -145 and -155 expression.
📍

Where

1 site
Pauls Stradins Clinical University hospital
Riga, Latvia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy